Search
Darolutamide
go.drugbank.com/drugs/DB12941ApprovedInvestigationalDarolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). … This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists.
Categories: Androgen Receptor InhibitorsIsopropyl myristate
go.drugbank.com/drugs/DB13966Approved[A178078] At the moment the primary usage for which isopropyl myristate is formally indicated is as the active ingredient in a non-prescription pediculicide rinse [A32333, L1964, L1966]. … Isopropyl myristate is a moisturizer with polar characteristics used in cosmetics and topical medical preparations to ameliorate the skin absorption.
Vandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalOn April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. … Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
Bismuth subnitrate
go.drugbank.com/drugs/DB13209ApprovedWithdrawnThe use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA. … Bismuth subnitrate, also referred to as bismuth oxynitrate or bismuthyl nitrate, is a highly water-soluble crystalline compound that has been used as a treatment for duodenal ulcers and anti-diarrheic
Chlorzoxazone
go.drugbank.com/drugs/DB00356ApprovedIt is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
Sibeprenlimab
go.drugbank.com/drugs/DB18919ApprovedInvestigational[L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628] … [L54633] APRIL is a member of the tumour necrosis factor superfamily that regulates and modulates activated B cells.
Gabapentin
go.drugbank.com/drugs/DB00996ApprovedInvestigationalGabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. … [L8717] It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to treat neuropathic pain.
Pembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1. … [A7624] In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers.
Categories: Programmed Death Receptor-1 Blocking Antibody, Programmed Death Receptor-1-directed Antibody InteractionsDiroximel fumarate
go.drugbank.com/drugs/DB14783ApprovedInvestigational[A187535] Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. … This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure.
Emapalumab
go.drugbank.com/drugs/DB14724ApprovedInvestigational[L4840] As well, emapalumab was given the status of PRIME by the EMA.[L4845] … [A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy.